| 1 | Antifungal Policy and Practice Across Five Countries: A Qualitative Review | 3.4 | 5 | Citations (PDF) |
| 2 | Baseline knowledge on chronic pulmonary aspergillosis and tuberculosis among health care workers involved in tuberculosis care in Uganda | 1.5 | 1 | Citations (PDF) |
| 3 | Survey of current national and international guidance to reduce risk of aspergillosis in hospitals | 2.3 | 2 | Citations (PDF) |
| 4 | Aspergillus
IgG antibody testing in the diagnosis of hypersensitivity pneumonitis: A scoping review | 1.7 | 5 | Citations (PDF) |
| 5 | A Silent Threat in Post-Tuberculosis Patients: Chronic Pulmonary Aspergillosis Survey in Multiple Regions of Indonesia (I-CHROME Study) | 3.4 | 5 | Citations (PDF) |
| 6 | Radiological features of chronic pulmonary histoplasmosis: Easily mistaken for tuberculosis | 3.0 | 4 | Citations (PDF) |
| 7 | Emergence of highly resistant Candida auris in the United Arab Emirates: a retrospective analysis of evolving national trends | 2.7 | 21 | Citations (PDF) |
| 8 | Frequency of fungal pathogens in autopsy studies of people who died with HIV in Africa: a scoping review | 5.3 | 13 | Citations (PDF) |
| 9 | Chronic Pulmonary Aspergillosis: Clinical Presentation and Management | 2.2 | 30 | Citations (PDF) |
| 10 | The Nairobi Declaration 2023: A commitment to address deadly yet neglected fungal diseases in Africa | 0.6 | 7 | Citations (PDF) |
| 11 | A Systematic Review of the Therapeutic Outcome of Mucormycosis | 0.8 | 37 | Citations (PDF) |
| 12 | Global incidence and mortality of severe fungal disease | 16.5 | 1,296 | Citations (PDF) |
| 13 | Re-estimation of the burden of serious fungal diseases in Uganda | 1.2 | 6 | Citations (PDF) |
| 14 | Estimated burden of fungal infections in Panama | 1.7 | 4 | Citations (PDF) |
| 15 | A diverse spectrum of mycoses histologically diagnosed in Ghana: Insights from a 10-year retrospective study | 0.6 | 4 | Citations (PDF) |
| 16 | Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses | 8.7 | 215 | Citations (PDF) |
| 17 | Renaming Candida glabrata—A case of taxonomic purity over clinical and public health pragmatism | 4.4 | 22 | Citations (PDF) |
| 18 | The incidence and prevalence of serious fungal diseases in Tunisia | 1.7 | 5 | Citations (PDF) |
| 19 | Triazole antifungal drug interactions—practical considerations for excellent prescribing | 3.1 | 32 | Citations (PDF) |
| 20 | Mapping the Burden of Fungal Diseases in the United Arab Emirates | 3.4 | 7 | Citations (PDF) |
| 21 | Pooled sample testing strategy for Aspergillus IgG-IgM serology in Uganda: A proof-of-concept and cost-effectiveness analysis | 1.5 | 2 | Citations (PDF) |
| 22 | Chronic pulmonary aspergillosis: a neglected post-TB lung disease | 1.3 | 5 | Citations (PDF) |
| 23 | Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens | 0.6 | 16 | Citations (PDF) |
| 24 | Aspergillus fumigatus—a systematic review to inform the World Health Organization priority list of fungal pathogens | 0.6 | 43 | Citations (PDF) |
| 25 | The Association of Chronic Pulmonary Aspergillosis and Chronic Pulmonary Histoplasmosis with MDR-TB Patients in Indonesia | 3.4 | 12 | Citations (PDF) |
| 26 | Primary treatment of chronic pulmonary aspergillosis with weekly liposomal amphotericin B: A case report from Uganda | 1.3 | 1 | Citations (PDF) |
| 27 | Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings | 16.5 | 18 | Citations (PDF) |
| 28 | Timing of recurrence after treatment of pulmonary TB 2024, 1, 456-465 | | 9 | Citations (PDF) |
| 29 | Fungal disease incidence and prevalence in Iraq – Preliminary estimates | 1.7 | 5 | Citations (PDF) |
| 30 | AreAspergillusspp. driving COPD exacerbations? | 8.7 | 1 | Citations (PDF) |
| 31 | New estimation of the prevalence of chronic pulmonary aspergillosis (CPA) related to pulmonary TB – a revised burden for India | 1.5 | 43 | Citations (PDF) |
| 32 | Importance of Aspergillus-Specific Antibody Screening for Diagnosis of Chronic Pulmonary Aspergillosis after Tuberculosis Treatment: A Prospective Follow-Up Study in Ghana | 3.4 | 8 | Citations (PDF) |
| 33 | Updated estimation of the burden of fungal disease in Vietnam | 3.2 | 17 | Citations (PDF) |
| 34 | The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease | 2.9 | 36 | Citations (PDF) |
| 35 | A multicenter survey of asymptomatic cryptococcal antigenemia among patients with advanced HIV disease in Nigeria | 2.1 | 10 | Citations (PDF) |
| 36 | Diagnostic options for pulmonary fungal diseases in Africa | 2.5 | 8 | Citations (PDF) |
| 37 | Invasive Aspergillosis after Renal Transplantation | 3.4 | 21 | Citations (PDF) |
| 38 | The Impact of Corticosteroids on the Outcome of Fungal Disease: a Systematic Review and Meta-analysis | 3.1 | 72 | Citations (PDF) |
| 39 | Gastrointestinal Histoplasmosis: A Descriptive Review, 2001–2021 | 2.6 | 16 | Citations (PDF) |
| 40 | Antibodies against Histoplasma capsulatum and Aspergillus fumigatus among chronic TB patients in Indonesia: a cross-sectional study | 0.6 | 6 | Citations (PDF) |
| 41 | Fungal infections in Algeria | 3.2 | 9 | Citations (PDF) |
| 42 | Flucytosine and its clinical usage | 1.2 | 47 | Citations (PDF) |
| 43 | The incidence of histoplasmosis and cryptococcal antigenemia among patients attending a large HIV clinic in Trinidad | 1.6 | 7 | Citations (PDF) |
| 44 | Burden of fungal infections in Kenya | 4.1 | 13 | Citations (PDF) |
| 45 | The SSS revolution in fungal diagnostics: speed, simplicity and sensitivity | 3.9 | 24 | Citations (PDF) |
| 46 | Modelling the impact of non-pharmaceutical interventions on workplace transmission of SARS-CoV-2 in the home-delivery sector | 2.3 | 5 | Citations (PDF) |
| 47 | Fungal Nomenclature: Managing Change Is the Name of the Game | 0.8 | 6 | Citations (PDF) |
| 48 | Poorly controlled asthma – Easy wins and future prospects for addressing fungal allergy | 4.7 | 26 | Citations (PDF) |
| 49 | Infection of bats with Histoplasma species | 0.6 | 28 | Citations (PDF) |
| 50 | Diagnostic capacity for fungal keratitis in Africa – Survey in 50 African countries | 4.3 | 3 | Citations (PDF) |
| 51 | Fungal infections in Sudan: An underestimated health problem | 3.0 | 11 | Citations (PDF) |
| 52 | Fungal Infections in the Caribbean: A Review of the Literature to Date | 3.4 | 5 | Citations (PDF) |
| 53 | Isolated renal and urinary tract aspergillosis: a systematic review | 3.0 | 11 | Citations (PDF) |
| 54 | Atypical presentation of asthma patients with airway fungal infection presenting with possible pulmonary tuberculosis 2023, 1, 37-46 | | 1 | Citations (PDF) |
| 55 | A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL) | 5.6 | 37 | Citations (PDF) |
| 56 | Defective Interferon-Gamma Production Is Common in Chronic Pulmonary Aspergillosis | 3.7 | 26 | Citations (PDF) |
| 57 | Prospective Evaluation of Positivity Rates of Aspergillus-Specific IgG and Quality of Life in HIV-Negative Tuberculosis Patients in Lagos, Nigeria | 4.1 | 8 | Citations (PDF) |
| 58 | Histoplasmosis in Africa: Current perspectives, knowledge gaps, and research priorities | 3.0 | 34 | Citations (PDF) |
| 59 | Burden of serious fungal infections in Honduras | 3.2 | 7 | Citations (PDF) |
| 60 | Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement | 8.7 | 25 | Citations (PDF) |
| 61 | Unravelling the Molecular Identification and Antifungal Susceptibility Profiles of Aspergillus spp. Isolated from Chronic Pulmonary Aspergillosis Patients in Jakarta, Indonesia: The Emergence of Cryptic Species | 3.4 | 12 | Citations (PDF) |
| 62 | Chronic pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in Uganda | 3.2 | 20 | Citations (PDF) |
| 63 | Estimated Incidence and Prevalence of Serious Fungal Infections in Morocco | 3.4 | 7 | Citations (PDF) |
| 64 | Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis | 3.4 | 26 | Citations (PDF) |
| 65 | Pulmonary and Extrapulmonary Manifestations of Fungal Infections Misdiagnosed as Tuberculosis: The Need for Prompt Diagnosis and Management | 3.4 | 61 | Citations (PDF) |
| 66 | Current situation of fungal diseases in Eritrea | 3.2 | 9 | Citations (PDF) |
| 67 | Cryptococcal and Histoplasma Antigen Screening Among People With Human Immunodeficiency Virus in Ghana and Comparative Analysis of OIDx Histoplasma Lateral Flow Assay and IMMY Histoplasma Enzyme Immunoassay | 0.8 | 30 | Citations (PDF) |
| 68 | Agility and Sustainability: A Qualitative Evaluation of COVID-19 Non-pharmaceutical Interventions in the UK Logistics Sector | 2.7 | 11 | Citations (PDF) |
| 69 | Chronic Respiratory Diseases Burden and Healthcare Facilities | 0.1 | 0 | Citations (PDF) |
| 70 | Triazole resistance in Aspergillus fumigatus isolates in Africa: a systematic review | 0.6 | 14 | Citations (PDF) |
| 71 | Chronic pulmonary aspergillosis is common among patients with presumed tuberculosis relapse in Ghana | 0.6 | 25 | Citations (PDF) |
| 72 | The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis | 16.5 | 567 | Citations (PDF) |
| 73 | P388 High rate of chronic pulmonary aspergillosis in active TB patients in Indonesia with GeneXpert positive | 0.6 | 0 | Citations (PDF) |
| 74 | P286 Histoplasmosis in Sri Lanka | 0.6 | 1 | Citations (PDF) |
| 75 | P143 Incidence of chronic pulmonary aspergillosis in a cohort of bacteriologically confirmed TB patients at a tertiary hospital in Ghana | 0.6 | 0 | Citations (PDF) |
| 76 | P482 Burden of serious fungal infections in India | 0.6 | 0 | Citations (PDF) |
| 77 | Diagnosing disseminated histoplasmosis in advanced HIV/AIDS disease in Cameroon using a point of care lateral flow assay | 1.2 | 1 | Citations (PDF) |
| 78 | The Case for Fungal Keratitis to Be Accepted as a Neglected Tropical Disease | 3.4 | 36 | Citations (PDF) |
| 79 | Quantifying Deaths from Aspergillosis in HIV Positive People | 3.4 | 26 | Citations (PDF) |
| 80 | Are platelet volume indices of clinical use in COVID-19? A systematic review | 2.4 | 14 | Citations (PDF) |
| 81 | Burden of Serious Fungal Infections in India | 0.8 | 65 | Citations (PDF) |
| 82 | Estimates of serious fungal infection burden in Côte d’Ivoire and country health profile | 1.7 | 20 | Citations (PDF) |
| 83 | The global incidence and diagnosis of fungal keratitis | 16.5 | 436 | Citations (PDF) |
| 84 | The burden of serious fungal infections in Azerbaijan | 1.2 | 4 | Citations (PDF) |
| 85 | The burden of serious fungal infections in Sierra Leone: a national estimate | 1.2 | 9 | Citations (PDF) |
| 86 | Drug–drug interaction database for safe prescribing of systemic antifungal agents | 1.2 | 8 | Citations (PDF) |
| 87 | BronchUK: protocol for an observational cohort study and biobank in bronchiectasis | 2.5 | 8 | Citations (PDF) |
| 88 | Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect Aspergillus-specific antibodies in chronic pulmonary aspergillosis | 2.6 | 26 | Citations (PDF) |
| 89 | Performance of LDBio Aspergillus WB and ICT Antibody Detection in Chronic Pulmonary Aspergillosis | 3.4 | 17 | Citations (PDF) |
| 90 | A Rapid Screening Program for Histoplasmosis, Tuberculosis, and Cryptococcosis Reduces Mortality in HIV Patients from Guatemala | 3.4 | 45 | Citations (PDF) |
| 91 | Histoplasmosis in the Republic of Congo dominated by African histoplasmosis, Histoplasma capsulatum var. duboisii | 3.0 | 23 | Citations (PDF) |
| 92 | Fungal asthma among Ugandan adult asthmatics | 0.6 | 12 | Citations (PDF) |
| 93 | Evaluation of an Aspergillus IgG/IgM lateral flow assay for serodiagnosis of fungal asthma in Uganda | 2.3 | 12 | Citations (PDF) |
| 94 | Screening for acute disseminated histoplasmosis in HIV disease using urinary antigen detection enzyme immunoassay: A pilot study in Cameroon | 1.7 | 18 | Citations (PDF) |
| 95 | Serious fungal disease incidence and prevalence in Indonesia | 3.2 | 30 | Citations (PDF) |
| 96 | Serious fungal diseases in Democratic Republic of Congo – Incidence and prevalence estimates | 3.2 | 16 | Citations (PDF) |
| 97 | Histoplasmosis in Children; HIV/AIDS Not a Major Driver | 3.4 | 18 | Citations (PDF) |
| 98 | Chronic Pulmonary Aspergillosis Situation among Post Tuberculosis Patients in Vietnam: An Observational Study | 3.4 | 36 | Citations (PDF) |
| 99 | Determining the burden of fungal infections in Zimbabwe | 3.4 | 22 | Citations (PDF) |
| 100 | Characterisation of Aspergillus fumigatus Endocytic Trafficking within Airway Epithelial Cells Using High-Resolution Automated Quantitative Confocal Microscopy | 3.4 | 19 | Citations (PDF) |
| 101 | Diagnosing pulmonary aspergillosis is much easier than it used to be: a new diagnostic landscape | 1.3 | 32 | Citations (PDF) |
| 102 | Impact of the COVID-19 pandemic on HIV care in Guatemala | 2.1 | 23 | Citations (PDF) |
| 103 | Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities | 1.3 | 41 | Citations (PDF) |
| 104 | The global burden of chromoblastomycosis | 3.0 | 85 | Citations (PDF) |
| 105 | Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials? | 0.8 | 5 | Citations (PDF) |
| 106 | Updated estimated incidence and prevalence of serious fungal infections in Trinidad and Tobago | 1.5 | 4 | Citations (PDF) |
| 107 | Estimated burden of serious fungal infections in Togo | 3.2 | 6 | Citations (PDF) |
| 108 | Prevalence of Aspergillus fumigatus skin positivity in adults without an apparent/known atopic disease in Uganda | 1.2 | 3 | Citations (PDF) |
| 109 | One Health aspects & priority roadmap for fungal diseases | 1.8 | 42 | Citations (PDF) |
| 110 | Standardization of Aspergillus IgG diagnostic cutoff in Nigerians | 1.2 | 6 | Citations (PDF) |
| 111 | Risk factors associated with respiratory infectious disease-related presenteeism: a rapid review | 3.1 | 46 | Citations (PDF) |
| 112 | Estimated Burden of Fungal Infections in Oman | 3.4 | 11 | Citations (PDF) |
| 113 | Evaluation of multiple open-source deep learning models for detecting and grading COVID-19 on chest radiographs | 1.2 | 0 | Citations (PDF) |
| 114 | Incidence of Histoplasmosis in a Cohort of People with HIV: From Estimations to Reality | 3.8 | 24 | Citations (PDF) |
| 115 | Recovery from Copperhead Snake Envenomation: Role of Age, Sex, Bite Location, Severity, and Treatment | 1.4 | 5 | Citations (PDF) |
| 116 | The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala | 0.8 | 33 | Citations (PDF) |
| 117 | Bridging the knowledge gap on mycoses in Africa: Setting up a Pan‐African Mycology Working Group | 3.2 | 31 | Citations (PDF) |
| 118 | High-volume culture and quantitative real-time PCR for the detection of Aspergillus in sputum | 5.3 | 77 | Citations (PDF) |
| 119 | The global distribution of actinomycetoma and eumycetoma | 3.0 | 116 | Citations (PDF) |
| 120 | Human Fungal Infections in Kuwait—Burden and Diagnostic Gaps | 3.4 | 9 | Citations (PDF) |
| 121 | The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda | 4.9 | 150 | Citations (PDF) |
| 122 | The role of antifungals in the management of patients with severe asthma | 2.6 | 30 | Citations (PDF) |
| 123 | Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary aspergillosis (CPA) in Indonesia | 1.6 | 17 | Citations (PDF) |
| 124 | Comparative performance of the laboratory assays used by a Diagnostic Laboratory Hub for opportunistic infections in people living with HIVAids, 2020, 34, 1625-1632 | 2.5 | 33 | Citations (PDF) |
| 125 | Optimising the cut-off of the Bordier Aspergillus IgG ELISA for the diagnosis of chronic pulmonary aspergillosis | 1.7 | 8 | Citations (PDF) |
| 126 | Deciphering Aspergillus fumigatus cyp51A-mediated triazole resistance by pyrosequencing of respiratory specimens | 3.1 | 15 | Citations (PDF) |
| 127 | Evaluation of the LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis | 2.3 | 27 | Citations (PDF) |
| 128 | The global impact of Aspergillus infection on COPD | 2.4 | 93 | Citations (PDF) |
| 129 | The incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis | 2.6 | 4 | Citations (PDF) |
| 130 | Risk-Based Estimate of Human Fungal Disease Burden, China | 3.8 | 55 | Citations (PDF) |
| 131 | Impact of high baseline Aspergillus-specific IgG levels on weight and quality-of-life outcomes of patients with chronic pulmonary aspergillosis | 0.6 | 8 | Citations (PDF) |
| 132 | Chronic Pulmonary Histoplasmosis—A Scoping Literature Review | 0.8 | 58 | Citations (PDF) |
| 133 | The antiseptic Miramistin: a review of its comparative in vitro and clinical activity | 10.6 | 30 | Citations (PDF) |
| 134 | Threats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture | 4.4 | 497 | Citations (PDF) |
| 135 | Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically | 1.4 | 33 | Citations (PDF) |
| 136 | Intravenous therapy for chronic pulmonary aspergillosis: A systematic review and meta‐analysis | 3.2 | 13 | Citations (PDF) |
| 137 | Chronic Pulmonary Aspergillosis: Notes for a Clinician in a Resource-Limited Setting Where There Is No Mycologist | 3.4 | 52 | Citations (PDF) |
| 138 | European confederation of medical mycology expert consult—An ECMM excellence center initiative | 3.2 | 13 | Citations (PDF) |
| 139 | Current burden of serious fungal infections in Republic of Congo | 3.2 | 10 | Citations (PDF) |
| 140 | Re-drawing the Maps for Endemic Mycoses | 2.4 | 286 | Citations (PDF) |
| 141 | Pulmonary Aspergillosis in Patients with Suspected Ventilator-Associated Pneumonia in UK ICUs | 8.9 | 52 | Citations (PDF) |
| 142 | Tackling cryptococcal meningitis in Nigeria, one-step at a time; the impact of training | 2.3 | 7 | Citations (PDF) |
| 143 | Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy | 0.4 | 21 | Citations (PDF) |
| 144 | Mycetoma in Uganda: A neglected tropical disease | 3.0 | 38 | Citations (PDF) |
| 145 | Burden of serious fungal infections in the Netherlands | 3.2 | 36 | Citations (PDF) |
| 146 | Skin prick reactivity among asthmatics in East Africa | 3.5 | 15 | Citations (PDF) |
| 147 | Evaluation of knowledge and awareness of invasive fungal infections amongst resident doctors in Nigeria | 0.7 | 30 | Citations (PDF) |
| 148 | Prophylaxis and Treatment of Invasive Aspergillosis: Who and How of Prophylaxis, Treatment, and New Therapies | 3.5 | 2 | Citations (PDF) |
| 149 | Siemens Immulite Aspergillus-specific IgG assay for chronic pulmonary aspergillosis diagnosis | 0.6 | 22 | Citations (PDF) |
| 150 | Estimated burden of serious human fungal diseases in Turkey | 3.2 | 19 | Citations (PDF) |
| 151 | Prospective study of the serum Aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis | 2.6 | 24 | Citations (PDF) |
| 152 | National trends in incidence, prevalence and disability-adjusted life years of invasive aspergillosis in Iran: a systematic review and meta-analysis | 2.4 | 14 | Citations (PDF) |
| 153 | Estimated burden of fungal infections in Sweden | 3.2 | 13 | Citations (PDF) |
| 154 | The Burden of Serious Fungal Infections in Kyrgyzstan | 3.4 | 5 | Citations (PDF) |
| 155 | The Burden of Serious Fungal Infections in Tajikistan | 3.4 | 6 | Citations (PDF) |
| 156 | Mapping histoplasmosis in South East Asia – implications for diagnosis in AIDS | 6.3 | 65 | Citations (PDF) |
| 157 | An evaluation of nebulised amphotericin B deoxycholate (Fungizone®) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre | 3.2 | 16 | Citations (PDF) |
| 158 | Estimated Burden of Fungal Infections in Namibia | 3.4 | 15 | Citations (PDF) |
| 159 | Getting Histoplasmosis on the Map of International Recommendations for Patients with Advanced HIV Disease | 3.4 | 40 | Citations (PDF) |
| 160 | The Diagnosis of Fungal Neglected Tropical Diseases (Fungal NTDs) and the Role of Investigation and Laboratory Tests: An Expert Consensus Report | 2.1 | 52 | Citations (PDF) |
| 161 | Fungal Diseases in Taiwan—National Insurance Data and Estimation | 3.4 | 11 | Citations (PDF) |
| 162 | Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation | 8.7 | 152 | Citations (PDF) |
| 163 | Evaluation of LDBio
Aspergillus
ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis | 4.0 | 49 | Citations (PDF) |
| 164 | Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-
d
-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus | 4.4 | 70 | Citations (PDF) |
| 165 | Estimated Burden of Serious Fungal Infections in Ghana | 3.4 | 34 | Citations (PDF) |
| 166 | The case for paracoccidioidomycosis to be accepted as a neglected tropical (fungal) disease | 3.0 | 60 | Citations (PDF) |
| 167 | Burden of fungal asthma in Africa: A systematic review and meta-analysis | 2.3 | 51 | Citations (PDF) |
| 168 | Detection of Pneumocystis jirovecii by quantitative real-time PCR in oral rinses from Pneumocystis pneumonia asymptomatic human immunodeficiency virus patients | 1.7 | 9 | Citations (PDF) |
| 169 | The validity, reliability and minimal clinically important difference of the patient specific functional scale in snake envenomation | 2.3 | 19 | Citations (PDF) |
| 170 | The Burden of Fungal Infections in Ethiopia | 3.4 | 43 | Citations (PDF) |
| 171 | Diagnostic Aspects of Chronic Pulmonary Aspergillosis: Present and New Directions | 3.1 | 21 | Citations (PDF) |
| 172 | The role of medical mycology societies in combating invasive fungal infections in low‐ and middle‐income countries: A Nigerian model | 3.2 | 12 | Citations (PDF) |
| 173 | Inducible Cell Fusion Permits Use of Competitive Fitness Profiling in the Human Pathogenic Fungus Aspergillus fumigatus | 4.1 | 22 | Citations (PDF) |
| 174 | Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis | 3.1 | 13 | Citations (PDF) |
| 175 | Chronic pulmonary aspergillosis following pulmonary embolism | 1.3 | 5 | Citations (PDF) |
| 176 | Pulmonary cryptococcosis: A review of pathobiology and clinical aspects | 0.6 | 235 | Citations (PDF) |
| 177 | Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries | 16.5 | 88 | Citations (PDF) |
| 178 | Micafungin may be safely administered as outpatient parenteral antimicrobial therapy for chronic pulmonary aspergillosis | 3.2 | 17 | Citations (PDF) |
| 179 | In vitro and in vivo efficacy of miramistin against drug-resistant fungi | 1.7 | 18 | Citations (PDF) |
| 180 | Subacute Invasive Aspergillosis Associated With Sorafenib Therapy for Hepatocellular Carcinoma | 5.2 | 8 | Citations (PDF) |
| 181 | Receiver operating characteristic curve analysis of four Aspergillus -specific IgG assays for the diagnosis of chronic pulmonary aspergillosis | 1.6 | 45 | Citations (PDF) |
| 182 | Corticosteroid treatment is associated with increased filamentous fungal burden in allergic fungal disease | 6.1 | 93 | Citations (PDF) |
| 183 | F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis | 1.6 | 18 | Citations (PDF) |
| 184 | Acute kidney injury: an unusual complication of posaconazole use | 1.5 | 5 | Citations (PDF) |
| 185 | Incidence, prevalence and mortality of hepatobiliary & pancreatic malignancies at the global and regional level: 1990 to 2016. GBD 2016 study | 0.3 | 0 | Citations (PDF) |
| 186 | Burden of Serious Fungal Infections in Jordan | 3.4 | 24 | Citations (PDF) |
| 187 | Lung colonization by Aspergillus fumigatus is controlled by ZNF77 | 13.7 | 52 | Citations (PDF) |
| 188 | An Estimate of the Burden of Fungal Disease in Norway | 3.4 | 9 | Citations (PDF) |
| 189 | Nebulised N-Acetylcysteine for Unresponsive Bronchial Obstruction in Allergic Brochopulmonary Aspergillosis: A Case Series and Review of the Literature | 3.4 | 12 | Citations (PDF) |
| 190 | Histoplasma capsulatum antigen detection tests as an essential diagnostic tool for patients with advanced HIV disease in low and middle income countries: A systematic review of diagnostic accuracy studies | 3.0 | 57 | Citations (PDF) |
| 191 | Diagnosis and Management of Pneumocystis Pneumonia in Resource-poor Settings | 0.7 | 21 | Citations (PDF) |
| 192 | Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis | 2.3 | 88 | Citations (PDF) |
| 193 | Global burden of recurrent vulvovaginal candidiasis: a systematic review | 16.5 | 563 | Citations (PDF) |
| 194 | Estimated Burden of Serious Fungal Diseases in Serbia | 3.4 | 16 | Citations (PDF) |
| 195 | Estimating the Burden of Serious Fungal Infections in Uruguay | 3.4 | 13 | Citations (PDF) |
| 196 | Estimated Burden of Serious Fungal Infections in Malawi | 3.4 | 21 | Citations (PDF) |
| 197 | Anti-Aspergillus Activities of the Respiratory Epithelium in Health and Disease | 3.4 | 61 | Citations (PDF) |
| 198 | The Burden of Fungal Diseases in Romania | 3.4 | 18 | Citations (PDF) |
| 199 | Burden of Severe Fungal Infections in Burkina Faso | 3.4 | 17 | Citations (PDF) |
| 200 | Estimation of the Burden of Serious Human Fungal Infections in Malaysia | 3.4 | 25 | Citations (PDF) |
| 201 | Burden of Fungal Infections in Colombia | 3.4 | 40 | Citations (PDF) |
| 202 | The Burden of Serious Fungal Infections in Cameroon | 3.4 | 36 | Citations (PDF) |
| 203 | Estimated Burden of Serious Fungal Infections in Mozambique | 3.4 | 28 | Citations (PDF) |
| 204 | Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings | 3.8 | 128 | Citations (PDF) |
| 205 | Burden of Serious Fungal Infections in Argentina | 3.4 | 28 | Citations (PDF) |
| 206 | An Estimate of Severe and Chronic Fungal Diseases in the Republic of Kazakhstan | 3.4 | 9 | Citations (PDF) |
| 207 | Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria | 3.9 | 21 | Citations (PDF) |
| 208 | Mutations in EEA1 are associated with allergic bronchopulmonary aspergillosis and affect phagocytosis of Aspergillus fumigatus by human macrophages | 2.3 | 21 | Citations (PDF) |
| 209 | Prior subclinical histoplasmosis revealed in Nigeria using histoplasmin skin testing | 2.3 | 20 | Citations (PDF) |
| 210 | Histoplasmosis in Africa: An emerging or a neglected disease? | 3.0 | 169 | Citations (PDF) |
| 211 | Aspergillusarthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases | 0.6 | 27 | Citations (PDF) |
| 212 | Serious fungal infections in Pakistan | 2.6 | 52 | Citations (PDF) |
| 213 | Serious fungal infections in Chile | 2.6 | 19 | Citations (PDF) |
| 214 | Burden of fungal infections in Algeria | 2.6 | 28 | Citations (PDF) |
| 215 | Serious fungal infections in the Philippines | 2.6 | 30 | Citations (PDF) |
| 216 | Serious fungal infections in Thailand | 2.6 | 39 | Citations (PDF) |
| 217 | Serious fungal infections in Peru | 2.6 | 16 | Citations (PDF) |
| 218 | Serious fungal infections in Egypt | 2.6 | 42 | Citations (PDF) |
| 219 | Burden of serious fungal infections in Guatemala | 2.6 | 29 | Citations (PDF) |
| 220 | Serious fungal infections in Korea | 2.6 | 19 | Citations (PDF) |
| 221 | Burden of serious fungal infections in Bangladesh | 2.6 | 32 | Citations (PDF) |
| 222 | Serious fungal infections in Canada | 2.6 | 40 | Citations (PDF) |
| 223 | Predictors of mortality in chronic pulmonary aspergillosis | 8.7 | 163 | Citations (PDF) |
| 224 | Serious fungal infections in Portugal | 2.6 | 32 | Citations (PDF) |
| 225 | Serious fungal infections in Ecuador | 2.6 | 14 | Citations (PDF) |
| 226 | Serious fungal diseases in the Republic of Uzbekistan | 2.6 | 12 | Citations (PDF) |
| 227 | Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis | 16.5 | 1,894 | Citations (PDF) |
| 228 | World Health Organization Ranking of Antimicrobials According to Their Importance in Human Medicine | 5.2 | 14 | Citations (PDF) |
| 229 | Successful long-term terbinafine therapy in an asthmatic patient with Aspergillus sensitization and bronchiectasis | 1.3 | 6 | Citations (PDF) |
| 230 | The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial | 1.5 | 75 | Citations (PDF) |
| 231 | Estimation des infections fongiques en Algérie | 1.7 | 10 | Citations (PDF) |
| 232 | Genetic susceptibility to severe asthma with fungal sensitization | 1.2 | 41 | Citations (PDF) |
| 233 | Tuberculosis/cryptococcosis co-infection in China between 1965 and 2016 | 6.3 | 46 | Citations (PDF) |
| 234 | Emergence of Echinocandin Resistance Due to a Point Mutation in the
fks1
Gene of Aspergillus fumigatus in a Patient with Chronic Pulmonary Aspergillosis | 4.1 | 73 | Citations (PDF) |
| 235 | Aspergillus nodules in chronic granulomatous disease attributable to Aspergillus ochraceus | 1.3 | 10 | Citations (PDF) |
| 236 | Improvement of fungal disease identification and management: combined health systems and public health approaches | 16.5 | 66 | Citations (PDF) |
| 237 | Pulmonary and sinus fungal diseases in non-immunocompromised patients | 16.5 | 112 | Citations (PDF) |
| 238 | The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach | 3.1 | 75 | Citations (PDF) |
| 239 | Comparative performance of Aspergillus galactomannan ELISA and PCR in sputum from patients with ABPA and CPA | 1.7 | 30 | Citations (PDF) |
| 240 | Gastroesophageal Reflux Disease and Pulmonary Diseases Associated with Aspergillosis: Is There a Connection? | 2.4 | 3 | Citations (PDF) |
| 241 | Estimating the burden of invasive and serious fungal disease in the United Kingdom | 2.8 | 101 | Citations (PDF) |
| 242 | Aspergillosis and the role of mucins in cystic fibrosis | 2.0 | 31 | Citations (PDF) |
| 243 | Future Research Priorities in Fungal Resistance | 3.7 | 28 | Citations (PDF) |
| 244 | Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis | 2.4 | 32 | Citations (PDF) |
| 245 | A Cross-Sectional Survey to Measure the Prevalence of Chronic Pulmonary Aspergillosis (CPA) Complicating Pulmonary Tuberculosis in Northern Uganda | 0.8 | 1 | Citations (PDF) |
| 246 | Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic Capabilities | 3.8 | 87 | Citations (PDF) |
| 247 | Innate and Adaptive Immune Defects in Chronic Pulmonary Aspergillosis | 3.4 | 32 | Citations (PDF) |
| 248 | HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for “Prevention Is Better Than Cure”? | 3.4 | 42 | Citations (PDF) |
| 249 | Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision | 3.4 | 2,560 | Citations (PDF) |
| 250 | Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians | 1.3 | 79 | Citations (PDF) |
| 251 | A Review of Onychomycosis Due to Aspergillus Species | 2.4 | 87 | Citations (PDF) |
| 252 | Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis | 1.7 | 36 | Citations (PDF) |
| 253 | An investigation of antifungal stewardship programmes in England | 1.7 | 36 | Citations (PDF) |
| 254 | The burden of serious human fungal infections in Brazil | 3.2 | 130 | Citations (PDF) |
| 255 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America | 5.2 | 2,603 | Citations (PDF) |
| 256 | Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis | 2.8 | 36 | Citations (PDF) |
| 257 | Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized | 3.7 | 103 | Citations (PDF) |
| 258 | Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA) | 2.6 | 18 | Citations (PDF) |
| 259 | Global access to antifungal therapy and its variable cost | 3.1 | 162 | Citations (PDF) |
| 260 | Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study | 2.1 | 54 | Citations (PDF) |
| 261 | Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America | 5.2 | 361 | Citations (PDF) |
| 262 | An estimation of burden of serious fungal infections in France | 1.7 | 87 | Citations (PDF) |
| 263 | Aspergillus nodules; another presentation of Chronic Pulmonary Aspergillosis | 2.4 | 75 | Citations (PDF) |
| 264 | Microbial yield from physiotherapy assisted sputum production in respiratory outpatients | 2.4 | 18 | Citations (PDF) |
| 265 | Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence | 0.8 | 27 | Citations (PDF) |
| 266 | An estimate of the burden of serious fungal diseases in Greece | 2.6 | 34 | Citations (PDF) |
| 267 | Electrophilic, Activation-Free Fluorogenic Reagent for Labeling Bioactive Amines | 3.8 | 24 | Citations (PDF) |
| 268 | Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA) | 2.8 | 147 | Citations (PDF) |
| 269 | Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management | 8.7 | 934 | Citations (PDF) |
| 270 | Burden of serious fungal infections in the Dominican Republic | 3.7 | 21 | Citations (PDF) |
| 271 | Mitochondrial Complex I Is a Global Regulator of Secondary Metabolism, Virulence and Azole Sensitivity in Fungi | 2.3 | 45 | Citations (PDF) |
| 272 | Response to pneumococcal polysaccharide vaccination in patients with chronic and allergic aspergillosis | 3.1 | 23 | Citations (PDF) |
| 273 | The burden of fungal disease in Denmark | 3.2 | 24 | Citations (PDF) |
| 274 | The burden of serious fungal diseases in Russia | 3.2 | 40 | Citations (PDF) |
| 275 | Burden of fungal infections in Senegal | 3.2 | 34 | Citations (PDF) |
| 276 | Estimating the burden of fungal disease in Vietnam | 3.2 | 29 | Citations (PDF) |
| 277 | Burden of fungal infections in Qatar | 3.2 | 41 | Citations (PDF) |
| 278 | Cryptococcal disease and the burden of other fungal diseases in Uganda; Where are the knowledge gaps and how can we fill them? | 3.2 | 44 | Citations (PDF) |
| 279 | Burden of serious fungal infections in Belgium | 3.2 | 24 | Citations (PDF) |
| 280 | Burden of serious fungal infections in Tanzania | 3.2 | 38 | Citations (PDF) |
| 281 | Estimated burden of fungal infections in Germany | 3.2 | 51 | Citations (PDF) |
| 282 | Burden of serious fungal infections in Nepal | 3.2 | 33 | Citations (PDF) |
| 283 | Burden of serious fungal infections in Trinidad and Tobago | 3.2 | 20 | Citations (PDF) |
| 284 | Burden of serious fungal infections in Mexico | 3.2 | 43 | Citations (PDF) |
| 285 | Burden of serious fungal infections in Ukraine | 3.2 | 18 | Citations (PDF) |
| 286 | Improved Detection of Invasive Pulmonary Aspergillosis Arising during Leukemia Treatment Using a Panel of Host Response Proteins and Fungal Antigens | 2.3 | 23 | Citations (PDF) |
| 287 | Antibody testing in aspergillosis—quo vadis? | 0.6 | 102 | Citations (PDF) |
| 288 | Burden of serious fungal infections in the Czech Republic | 3.2 | 20 | Citations (PDF) |
| 289 | Burden of serious fungal diseases in Hungary | 3.2 | 17 | Citations (PDF) |
| 290 | Development of chronic pulmonary aspergillosis in adult asthmatics with ABPA | 2.6 | 36 | Citations (PDF) |
| 291 | Burden of fungal disease in Ireland | 1.7 | 30 | Citations (PDF) |
| 292 | Elevated Levels of the Neutrophil Chemoattractant Pro–Platelet Basic Protein in Macrophages From Individuals With Chronic and Allergic Aspergillosis | 3.7 | 28 | Citations (PDF) |
| 293 | Republished: The clinical spectrum of pulmonary aspergillosis | 1.6 | 42 | Citations (PDF) |
| 294 | Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) | 1.6 | 51 | Citations (PDF) |
| 295 | British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases | 16.5 | 187 | Citations (PDF) |
| 296 | Prospective Multicenter International Surveillance of Azole Resistance inAspergillus fumigatus | 3.8 | 367 | Citations (PDF) |
| 297 | International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus | 19.2 | 306 | Citations (PDF) |
| 298 | Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran | 2.6 | 62 | Citations (PDF) |
| 299 | Burden of serious fungal infections in Spain | 5.3 | 61 | Citations (PDF) |
| 300 | The clinical spectrum of pulmonary aspergillosis | 5.6 | 783 | Citations (PDF) |
| 301 | Is fungal disease in Sri Lanka underestimated? A comparison of reported fungal infections with estimated disease burden using global data | 0.0 | 1 | Citations (PDF) |
| 302 | Estimation of the Burden of Chronic and Allergic Pulmonary Aspergillosis in India | 2.3 | 107 | Citations (PDF) |
| 303 | Multi-Country Estimate of Different Manifestations of Aspergillosis in Cystic Fibrosis | 2.3 | 98 | Citations (PDF) |
| 304 | Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in Chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT | 5.3 | 40 | Citations (PDF) |
| 305 | A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis | 5.3 | 40 | Citations (PDF) |
| 306 | Occurrence of azole-resistant species of Aspergillus in the UK environment | 2.3 | 56 | Citations (PDF) |
| 307 | Clinical implications of interferon‐γ genetic and epigenetic variants | 4.7 | 49 | Citations (PDF) |
| 308 | Long-Term Stability at −20°C of Aspergillus Galactomannan in Serum and Bronchoalveolar Lavage Specimens | 4.0 | 17 | Citations (PDF) |
| 309 | Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options | 16.5 | 104 | Citations (PDF) |
| 310 | Posaconazole responsive cerebral aspergillosis in an immunocompetent adult | 1.6 | 8 | Citations (PDF) |
| 311 | Fungal allergy in asthma–state of the art and research needs | 2.6 | 304 | Citations (PDF) |
| 312 | AIDS-related mycoses: the way forward | 8.1 | 32 | Citations (PDF) |
| 313 | Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR | 3.2 | 79 | Citations (PDF) |
| 314 | High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates | 3.1 | 84 | Citations (PDF) |
| 315 | Long-term Antifungal Treatment Improves Health Status in Patients With Chronic Pulmonary Aspergillosis: A Longitudinal Analysis | 5.2 | 78 | Citations (PDF) |
| 316 | Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence - a National Centre’s experience | 1.3 | 105 | Citations (PDF) |
| 317 | IgE-Mediated Immune Responses and Airway Detection of Aspergillus and Candida in Adult Cystic FibrosisChest, 2013, 143, 1351-1357 | 1.0 | 79 | Citations (PDF) |
| 318 | Acute Aspergillus pneumonia associated with mouldy tree bark-chippings, complicated by anti-glomerular basement membrane disease causing permanent renal failure | 1.3 | 11 | Citations (PDF) |
| 319 | Novel immunologic classification of aspergillosis in adult cystic fibrosis | 6.1 | 198 | Citations (PDF) |
| 320 | Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients | 1.7 | 51 | Citations (PDF) |
| 321 | Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis | 3.2 | 50 | Citations (PDF) |
| 322 | Global burden of chronic pulmonary aspergillosis complicating sarcoidosis | 8.7 | 172 | Citations (PDF) |
| 323 | The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus | 3.1 | 308 | Citations (PDF) |
| 324 | Frequency, diagnosis and management of fungal respiratory infections | 2.5 | 39 | Citations (PDF) |
| 325 | Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis | 5.3 | 89 | Citations (PDF) |
| 326 | Intravenous antibiotics reduce the presence ofAspergillusin adult cystic fibrosis sputum | 5.6 | 68 | Citations (PDF) |
| 327 | Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults | 0.6 | 455 | Citations (PDF) |
| 328 | Validity and Reliability of the St. George's Respiratory Questionnaire in Assessing Health Status in Patients With Chronic Pulmonary AspergillosisChest, 2013, 144, 623-631 | 1.0 | 51 | Citations (PDF) |
| 329 | Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy | 3.1 | 449 | Citations (PDF) |
| 330 | Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy | 3.1 | 5 | Citations (PDF) |
| 331 | Voriconazole and Posaconazole Improve Asthma Severity in Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitization | 1.6 | 130 | Citations (PDF) |
| 332 | Hidden Killers: Human Fungal Infections | 12.5 | 4,094 | Citations (PDF) |
| 333 | Allergic bronchopulmonary mycosis due to Alternaria: Case report and review | 1.3 | 18 | Citations (PDF) |
| 334 | Aspergillus bronchitis without significant immunocompromise | 4.0 | 89 | Citations (PDF) |
| 335 | Multifocal pulmonary aspergillomas: case series and review | 4.0 | 12 | Citations (PDF) |
| 336 | Fungi and allergic lower respiratory tract diseases | 6.1 | 452 | Citations (PDF) |
| 337 | Sequencing of mitochondrial genomes of nine Aspergillus and Penicillium species identifies mobile introns and accessory genes as main sources of genome size variability | 3.3 | 156 | Citations (PDF) |
| 338 | The Performance of Real-Time PCR, Galactomannan, and Fungal Culture in the Diagnosis of Invasive Aspergillosis in Ventilated Patients with Chronic Obstructive Pulmonary Disease (COPD) | 2.4 | 34 | Citations (PDF) |
| 339 | Mannose‐binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis | 1.2 | 39 | Citations (PDF) |
| 340 | Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus | 1.9 | 40 | Citations (PDF) |
| 341 | High-frequency Triazole Resistance Found In Nonculturable Aspergillus fumigatus from Lungs of Patients with Chronic Fungal Disease | 5.2 | 293 | Citations (PDF) |
| 342 | Allergic Bronchopulmonary Aspergillosis and Related Allergic Syndromes | 2.2 | 78 | Citations (PDF) |
| 343 | Homogenisation of cystic fibrosis sputum by sonication — An essential step for Aspergillus PCR | 1.7 | 44 | Citations (PDF) |
| 344 | Detrimental effect of propylene glycol on natural killer cell and neutrophil function | 2.9 | 7 | Citations (PDF) |
| 345 | Aspergillus fumigatus Bronchopneumonia in a Hellenic Shepherd Dog | 1.0 | 19 | Citations (PDF) |
| 346 | Invasive Aspergillosis in a patient with Asthma post H1N1 PneumoniaD Nayar1, Cook P1, Lim L1, Allison D1, Denning D2County Durham and Darlington Foundation Trust1National Aspergillosis Centre, University Hospital of South Manchester2 | 2.8 | 2 | Citations (PDF) |
| 347 | Azole Antifungal Resistance Today: Focus on Aspergillus | 2.6 | 45 | Citations (PDF) |
| 348 | Itraconazole associated quadriparesis and edema: a case report | 0.9 | 8 | Citations (PDF) |
| 349 | Interrogation of Related Clinical Pan-Azole-Resistant Aspergillus fumigatus Strains: G138C, Y431C, and G434C Single Nucleotide Polymorphisms incyp51A, Upregulation ofcyp51A, and Integration and Activation of TransposonAtf1in thecyp51APromoter | 4.1 | 93 | Citations (PDF) |
| 350 | Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma | 8.7 | 417 | Citations (PDF) |
| 351 | Cryptic Species and Azole Resistance in the Aspergillus niger Complex | 4.1 | 130 | Citations (PDF) |
| 352 | Peripheral neuropathy in patients on long-term triazole antifungal therapy | 3.1 | 62 | Citations (PDF) |
| 353 | A public resource for metabolic pathway mapping ofAspergillus fumigatusAf293 | 0.6 | 8 | Citations (PDF) |
| 354 | Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography | 5.6 | 57 | Citations (PDF) |
| 355 | Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis | 2.0 | 383 | Citations (PDF) |
| 356 | Multicenter, Prospective Clinical Evaluation of Respiratory Samples from Subjects at Risk for Pneumocystis jirovecii Infection by Use of a Commercial Real-Time PCR Assay | 4.0 | 90 | Citations (PDF) |
| 357 | Candida tropicalisin human disease | 6.2 | 114 | Citations (PDF) |
| 358 | Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort | 2.6 | 45 | Citations (PDF) |
| 359 | Aspergillus fumigatus allergen expression is coordinately regulated in response to hydrogen peroxide and cyclic AMP | 2.6 | 10 | Citations (PDF) |
| 360 | Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis | 5.3 | 79 | Citations (PDF) |
| 361 | Molecular Detection and Identification of
Zygomycetes
Species from Paraffin-Embedded Tissues in a Murine Model of Disseminated Zygomycosis: a Collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) Evaluation | 4.0 | 88 | Citations (PDF) |
| 362 | Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis | 5.2 | 139 | Citations (PDF) |
| 363 | Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009 | 3.1 | 314 | Citations (PDF) |
| 364 | A 27-Year-Old Woman With Acute, Severe Asthma Who Developed Respiratory FailureChest, 2010, 137, 724-727 | 1.0 | 0 | Citations (PDF) |
| 365 | Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus | 3.9 | 36 | Citations (PDF) |
| 366 | Aspergillus DNA contamination in blood collection tubes | 1.6 | 56 | Citations (PDF) |
| 367 | Therapy for fungal diseases: opportunities and priorities | 8.1 | 285 | Citations (PDF) |
| 368 | Genetic variability of innate immunity impacts human susceptibility to fungal diseases | 2.1 | 57 | Citations (PDF) |
| 369 | Frequency and Evolution of Azole Resistance inAspergillus fumigatusAssociated with Treatment Failure1 | 3.8 | 755 | Citations (PDF) |
| 370 | Using aCGH to study intraspecific genetic variability in two pathogenic molds,Aspergillus fumigatusandAspergillus flavus | 0.6 | 16 | Citations (PDF) |
| 371 | In vitro susceptibility of non-Aspergillus allergenic fungal species to azoles | 3.1 | 3 | Citations (PDF) |
| 372 | Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect | 4.1 | 83 | Citations (PDF) |
| 373 | Randomized Controlled Trial of Oral Antifungal Treatment for Severe Asthma with Fungal Sensitization | 8.9 | 340 | Citations (PDF) |
| 374 | Aspergillus Genomes and the Aspergillus Cloud | 15.5 | 17 | Citations (PDF) |
| 375 | Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring | 5.2 | 131 | Citations (PDF) |
| 376 | Fungal rhinosinusitis | 1.4 | 457 | Citations (PDF) |
| 377 | Aflatoxin and Ochratoxin Production by Aspergillus Species Under Ex Vivo Conditions | 2.4 | 19 | Citations (PDF) |
| 378 | Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma | 2.4 | 158 | Citations (PDF) |
| 379 | Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy | 3.3 | 23 | Citations (PDF) |
| 380 | The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis | 4.0 | 65 | Citations (PDF) |
| 381 | Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis | 2.2 | 120 | Citations (PDF) |
| 382 | Standards of care for patients with invasive fungal infections within the United Kingdom: A national audit | 2.8 | 35 | Citations (PDF) |
| 383 | Excess mortality, length of stay and cost attributable to candidaemia | 2.8 | 71 | Citations (PDF) |
| 384 | Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints | 19.2 | 240 | Citations (PDF) |
| 385 | Invasive pulmonary aspergillosis 10 years post bone marrow transplantation: a case report | 0.9 | 2 | Citations (PDF) |
| 386 | Does Itraconazole Improve Quality of Life in Severe Asthma with Fungal Sensitization? | 8.9 | 2 | Citations (PDF) |
| 387 | A study on Aspergillus species in houses of asthmatic patients from Sari City, Iran and a brief review of the health effects of exposure to indoor Aspergillus | 2.9 | 55 | Citations (PDF) |
| 388 | EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts | 5.3 | 498 | Citations (PDF) |
| 389 | Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED | 3.3 | 49 | Citations (PDF) |
| 390 | A case of spotted fever group rickettsiosis imported into the United Kingdom and treated with ciprofloxacin: a case report | 0.9 | 4 | Citations (PDF) |
| 391 | An aspergilloma caused byAspergillus flavus | 0.6 | 27 | Citations (PDF) |
| 392 | Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group | 5.2 | 4,705 | Citations (PDF) |
| 393 | Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America | 5.2 | 2,557 | Citations (PDF) |
| 394 | Voriconazole plasma monitoring | 2.3 | 42 | Citations (PDF) |
| 395 | New and emerging treatments for fungal infections | 3.1 | 160 | Citations (PDF) |
| 396 | Genomic Islands in the Pathogenic Filamentous Fungus Aspergillus fumigatus | 3.2 | 510 | Citations (PDF) |
| 397 | Polymorphisms in Toll‐Like Receptor Genes and Susceptibility to Pulmonary Aspergillosis | 3.7 | 242 | Citations (PDF) |
| 398 | Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei | 3.1 | 55 | Citations (PDF) |
| 399 | Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I | 4.0 | 193 | Citations (PDF) |
| 400 | Chronic mucocutaneous candidiasis and oesophageal cancer | 0.6 | 54 | Citations (PDF) |
| 401 | Therapeutic drug monitoring for triazoles | 3.3 | 130 | Citations (PDF) |
| 402 | Flucytosine therapeutic monitoring: 15 years experience from the UK | 3.1 | 68 | Citations (PDF) |
| 403 | Statistical Analyses of Correlation between Fluconazole MICs for
Candida
spp. Assessed by Standard Methods Set Forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2) | 4.0 | 51 | Citations (PDF) |
| 404 | Optimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing | 4.1 | 23 | Citations (PDF) |
| 405 | Does One Voriconazole Breakpoint Suit All
Candida
Species? | 4.0 | 8 | Citations (PDF) |
| 406 | Reply to Verweij et al | 5.2 | 5 | Citations (PDF) |
| 407 | Comparison of 2 Studies of Treatment of Invasive Aspergillosis | 5.2 | 14 | Citations (PDF) |
| 408 | Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis | 2.3 | 108 | Citations (PDF) |
| 409 | Effect of Neutropenia and Treatment Delay on the Response to Antifungal Agents in Experimental Disseminated Candidiasis | 4.1 | 36 | Citations (PDF) |
| 410 | A Cautionary Tale: Lack of Consistency in Allele Sizes between Two Laboratories for a Published Multilocus Microsatellite Typing System | 4.0 | 92 | Citations (PDF) |
| 411 | What can comparative genomics tell us about species concepts in the genus Aspergillus? | 8.5 | 95 | Citations (PDF) |
| 412 | Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign | 5.2 | 563 | Citations (PDF) |
| 413 | Genomic analysis of allergen genes in Aspergillus spp.: the relevance of genomics to everyday research | 0.6 | 47 | Citations (PDF) |
| 414 | Aspergillus flavus: human pathogen, allergen and mycotoxin producer | 2.9 | 806 | Citations (PDF) |
| 415 | Résistance d´Aspergillus fumigatus à plusieurs dérivés azolés | 1.7 | 0 | Citations (PDF) |
| 416 | Multi-azole resistance in Aspergillus fumigatus | 3.9 | 207 | Citations (PDF) |
| 417 | Whole genome comparison of theA. fumigatusfamily | 0.6 | 42 | Citations (PDF) |
| 418 | The link between fungi and severe asthma: a summary of the evidence | 8.7 | 762 | Citations (PDF) |
| 419 | Voriconazole Treatment for Subacute Invasive and Chronic Pulmonary Aspergillosis | 2.0 | 98 | Citations (PDF) |
| 420 | Fungal contamination of bedding | 6.7 | 67 | Citations (PDF) |
| 421 | Comparison of two fluorescent whiteners, Calcofluor and Blankophor, for the detection of fungal elements in clinical specimens in the diagnostic laboratory | 5.3 | 50 | Citations (PDF) |
| 422 | Post-operative aspergillosis | 5.3 | 168 | Citations (PDF) |
| 423 | The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis | 2.8 | 86 | Citations (PDF) |
| 424 | Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis | 2.8 | 297 | Citations (PDF) |
| 425 | Antifungal susceptibility testing inAspergillusspp. according to EUCAST methodology | 0.6 | 64 | Citations (PDF) |
| 426 | Cytokine profiling of pulmonary aspergillosis | 1.2 | 81 | Citations (PDF) |
| 427 | Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues | 3.3 | 74 | Citations (PDF) |
| 428 | Relative reactivity ofAspergillusallergens used in serological tests | 0.6 | 18 | Citations (PDF) |
| 429 | Audit of laboratory mycology services for the management of patients with fungal infections in the northwest of England | 1.7 | 6 | Citations (PDF) |
| 430 | In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. | 3.1 | 89 | Citations (PDF) |
| 431 | Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt | 5.2 | 3 | Citations (PDF) |
| 432 | Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? | 3.1 | 170 | Citations (PDF) |
| 433 | Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against
Candida albicans
and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect | 4.1 | 49 | Citations (PDF) |
| 434 | Acute pulmonary aspergillosis in immunocompetent subjects after exposure to bark chippings | 1.5 | 27 | Citations (PDF) |
| 435 | Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus | 3.1 | 74 | Citations (PDF) |
| 436 | Sub-cutaneous phaeohyphomycosis caused byCladophialophora devriesiiin a United Kingdom resident | 0.6 | 9 | Citations (PDF) |
| 437 | Genome sequencing and analysis of Aspergillus oryzae | 37.9 | 1,234 | Citations (PDF) |
| 438 | Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus | 37.9 | 1,337 | Citations (PDF) |
| 439 | Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae | 37.9 | 1,308 | Citations (PDF) |
| 440 | Genomics of Aspergillus fumigatus | 1.0 | 43 | Citations (PDF) |
| 441 | Invasive pulmonary aspergillosis transformed into fatal mucous impaction by immune reconstitution in an AIDS patient | 2.6 | 19 | Citations (PDF) |
| 442 | Advances against aspergillosis (September 9?11, 2004, San Francisco, California) | 2.4 | 1 | Citations (PDF) |
| 443 | Book Review M.A. Klich, Identification of Common Aspergillus Species, ASM Press, Washington, DC, 2002, 116 pp., $39.95. | 2.4 | 1 | Citations (PDF) |
| 444 | Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions | 2.4 | 221 | Citations (PDF) |
| 445 | Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome | 5.2 | 111 | Citations (PDF) |
| 446 | Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis | 3.1 | 33 | Citations (PDF) |
| 447 | Surface Response Modeling to Examine the Combination of Amphotericin B Deoxycholate and 5‐Fluorocytosine for Treatment of Invasive Candidiasis | 3.7 | 18 | Citations (PDF) |
| 448 | The invasive and saprophytic syndromes due toAspergillusspp. | 0.6 | 211 | Citations (PDF) |
| 449 | Laboratory diagnosis of invasive aspergillosis | 16.5 | 456 | Citations (PDF) |
| 450 | Correlation betweenin vitrogrowth rate andin vivovirulence inAspergillus fumigatus | 0.6 | 51 | Citations (PDF) |
| 451 | Evidence for recombination in Candida glabrata | 2.1 | 72 | Citations (PDF) |
| 452 | What theAspergillusgenomes have told us | 0.6 | 32 | Citations (PDF) |
| 453 | Diagnosis of Invasive Fungal Infections – Current Limitations of Classical and New Diagnostic Methods | 0.1 | 10 | Citations (PDF) |
| 454 | Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy | 5.2 | 642 | Citations (PDF) |
| 455 | Molecular Mechanisms of Primary Resistance to Flucytosine in
Candida albicans | 4.1 | 159 | Citations (PDF) |
| 456 | Adverse Reactions to Voriconazole | 5.2 | 184 | Citations (PDF) |
| 457 | Mycobacterium chelonae finger infection associated with Raynaud's phenomenon | 6.9 | 5 | Citations (PDF) |
| 458 | Inactivation of Transcription Factor Gene
ACE2
in the Fungal Pathogen
Candida glabrata
Results in Hypervirulence | 2.7 | 75 | Citations (PDF) |
| 459 | Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida | 3.1 | 45 | Citations (PDF) |
| 460 | Optimising antifungal therapy for individual patients | 0.8 | 5 | Citations (PDF) |
| 461 | Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist | 3.6 | 13 | Citations (PDF) |
| 462 | Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens | 2.8 | 5 | Citations (PDF) |
| 463 | CADRE: the Central Aspergillus Data REpository | 15.5 | 61 | Citations (PDF) |
| 464 | Comparison of extracellular phospholipase activities in clinical and environmentalAspergillus fumigatusisolates | 0.6 | 33 | Citations (PDF) |
| 465 | Insight into the genome of Aspergillus fumigatus: analysis of a 922kb region encompassing the nitrate assimilation gene cluster | 2.1 | 66 | Citations (PDF) |
| 466 | Validation of an Assay for Voriconazole in Serum Samples Using Liquid Chromatography-Tandem Mass Spectrometry | 1.8 | 68 | Citations (PDF) |
| 467 | Pulmonary Aspergillosis in a Patient with Chronic Granulomatous Disease: Confirmation by Polymerase Chain Reaction and Serological Tests, and Successful Treatment with Voriconazole | 2.6 | 14 | Citations (PDF) |
| 468 | Candida glabrata STE12 is required for wild-type levels of virulence and nitrogen starvation induced filamentation | 2.5 | 68 | Citations (PDF) |
| 469 | Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST) | 5.3 | 141 | Citations (PDF) |
| 470 | Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts | 5.3 | 157 | Citations (PDF) |
| 471 | Echinocandin antifungal drugs | 62.1 | 1,076 | Citations (PDF) |
| 472 | British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections | 16.5 | 187 | Citations (PDF) |
| 473 | Standards of care for invasive fungal infections – Authors' reply | 16.5 | 0 | Citations (PDF) |
| 474 | Advances against Aspergillosis | 5.2 | 20 | Citations (PDF) |
| 475 | Multilocus Sequence Typing of
Candidaglabrata
Reveals Geographically EnrichedClades | 4.0 | 189 | Citations (PDF) |
| 476 | Interlaboratory Evaluation of Hematocytometer Method of Inoculum Preparation for Testing Antifungal Susceptibilities of Filamentous Fungi | 4.0 | 75 | Citations (PDF) |
| 477 | Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections | 1.1 | 69 | Citations (PDF) |
| 478 | Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B | 3.1 | 68 | Citations (PDF) |
| 479 | Cutaneous childhood sarcoidosis--a rare disease refractory to treatment | 2.1 | 3 | Citations (PDF) |
| 480 | Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis—State of the Art: Cystic Fibrosis Foundation Consensus Conference | 5.2 | 721 | Citations (PDF) |
| 481 | Comparison of three methods for in vitro susceptibility testing of Candida species with flucytosine | 3.1 | 9 | Citations (PDF) |
| 482 | Chronic Cavitary and Fibrosing Pulmonary and Pleural Aspergillosis: Case Series, Proposed Nomenclature Change, and Review | 5.2 | 504 | Citations (PDF) |
| 483 | Combination and Sequential Antifungal Therapy for Invasive Aspergillosis: Review of Published In Vitro and In Vivo Interactions and 6281 Clinical Cases from 1966 to 2001 | 5.2 | 174 | Citations (PDF) |
| 484 | Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis | 5.2 | 832 | Citations (PDF) |
| 485 | In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. | 3.1 | 71 | Citations (PDF) |
| 486 | Azole Cross-Resistance in
Aspergillus fumigatus | 4.1 | 120 | Citations (PDF) |
| 487 | In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis | 3.1 | 33 | Citations (PDF) |
| 488 | Echinocandins: a new class of antifungal | 3.1 | 287 | Citations (PDF) |
| 489 | Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus | 5.2 | 2,324 | Citations (PDF) |
| 490 | Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis | 34.5 | 3,249 | Citations (PDF) |
| 491 | Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate | 2.1 | 195 | Citations (PDF) |
| 492 | Sequencing the Aspergillus fumigatus genome | 16.5 | 82 | Citations (PDF) |
| 493 | Aspergillosis | 3.1 | 292 | Citations (PDF) |
| 494 | Adverse drug reactions to the new triazole, voriconazole — the need for therapeutic drug monitoring | 2.8 | 0 | Citations (PDF) |
| 495 | IN VITRO MODEL OF THE TRANSLOCATION OF CANDIDA SPP. ACROSS THE GUT WALL | 3.2 | 0 | Citations (PDF) |
| 496 | Invasive Infection due to Penicillium Species other than P. marneffei | 2.8 | 117 | Citations (PDF) |
| 497 | Termination of development of D0870 | 3.1 | 13 | Citations (PDF) |
| 498 | Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole | 1.1 | 125 | Citations (PDF) |
| 499 | Fungal infection of the diabetic foot: two distinct syndromes | 2.9 | 35 | Citations (PDF) |
| 500 | In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species† †This study was presented, in part, at the 37th ICAAC in Toronto, Canada, 28th September – 1st October 1997. | 5.3 | 37 | Citations (PDF) |
| 501 | Chronic forms of pulmonary aspergillosis | 5.3 | 135 | Citations (PDF) |
| 502 | Antifungal Susceptibility Testing of Fluconazole by Flow Cytometry Correlates with Clinical Outcome | 4.0 | 35 | Citations (PDF) |
| 503 | Mannose‐Binding Lectin Gene Polymorphisms as a Susceptibility Factor for Chronic Necrotizing Pulmonary Aspergillosis | 3.7 | 150 | Citations (PDF) |
| 504 | A Phase III Study of Recombinant Human Interferon Gamma to Prevent Opportunistic Infections in Advanced HIV Disease | 1.4 | 60 | Citations (PDF) |
| 505 | In Vitro Activities of Terbinafine against
Aspergillus
Species in Comparison with Those of Itraconazole and Amphotericin B | 4.1 | 57 | Citations (PDF) |
| 506 | Susceptibility Testing of
Aspergillus flavus
: Inoculum Dependence with Itraconazole and Lack of Correlation between Susceptibility to Amphotericin B In Vitro and Outcome In Vivo | 4.1 | 61 | Citations (PDF) |
| 507 | Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses | 5.2 | 72 | Citations (PDF) |
| 508 | Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole | 3.1 | 21 | Citations (PDF) |
| 509 | Antifungal Drug Resistance in Aspergillus | 2.8 | 151 | Citations (PDF) |
| 510 | In Vivo Activity of Amphotericin B Lipid Complex in Immunocompromised Mice against Fluconazole-Resistant or Fluconazole-Susceptible
Candida tropicalis | 4.1 | 22 | Citations (PDF) |
| 511 | Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection | 3.1 | 100 | Citations (PDF) |
| 512 | Practice Guidelines for Diseases Caused by Aspergillus | 5.2 | 777 | Citations (PDF) |
| 513 | In Vitro Activity of the New Triazole BMS-207147 against
Aspergillus
Species in Comparison with Itraconazole and Amphotericin B | 4.1 | 71 | Citations (PDF) |
| 514 | Invasive Aspergillosis as an Opportunistic Infection in Nonallografted Patients with Multiple Myeloma: A European Organization for Research and Treatment of Cancer | 5.2 | 62 | Citations (PDF) |
| 515 | Molecular genetics in Aspergillus fumigatus | 7.0 | 80 | Citations (PDF) |
| 516 | SUCCESSFUL TREATMENT OF ASPERGILLUS BRAIN ABSCESS IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIA | 1.3 | 23 | Citations (PDF) |
| 517 | Early diagnosis of invasive aspergillosis | 62.1 | 56 | Citations (PDF) |
| 518 | Dose Range Evaluation of Liposomal Nystatin and Comparisons with Amphotericin B and Amphotericin B Lipid Complex in Temporarily Neutropenic Mice Infected with an Isolate of
Aspergillus fumigatus
with Reduced Susceptibility to Amphotericin B | 4.1 | 53 | Citations (PDF) |
| 519 | Comparison of In Vitro Activity of Liposomal Nystatin against
Aspergillus
Species with Those of Nystatin, Amphotericin B (AB) Deoxycholate, AB Colloidal Dispersion, Liposomal AB, AB Lipid Complex, and Itraconazole | 4.1 | 63 | Citations (PDF) |
| 520 | Discrepancies associated with the measurement of itraconazole serum concentrations by bioassays | 3.1 | 12 | Citations (PDF) |
| 521 | Assessment of Therapeutic Response of Oropharyngeal and Esophageal Candidiasis in AIDS with Use of a New Clinical Scoring System: Studies with D0870 | 5.2 | 6 | Citations (PDF) |
| 522 | Endemic mycoses: a treatment update | 3.1 | 114 | Citations (PDF) |
| 523 | The design, development and running of a website for medical education: The Aspergillus website as an example | 2.8 | 0 | Citations (PDF) |
| 524 | Aspergillus fumigatuscatalases: cloning of anAspergillus nidulanscatalase B homologue and evidence for at least three catalases | 3.0 | 31 | Citations (PDF) |
| 525 | Title is missing! | 2.4 | 24 | Citations (PDF) |
| 526 | Use of the 6-methylsalicylic-acid-synthase gene as a discriminating marker betweenaspergillus terreus andAspergillus flavipes | 2.9 | 5 | Citations (PDF) |
| 527 | Invasive yeast infections other than Candida spp. in acute leukaemia | 2.3 | 106 | Citations (PDF) |
| 528 | Activity of pradimicin BMS-181184 against Aspergillus spp | 3.9 | 9 | Citations (PDF) |
| 529 | An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome | 2.8 | 256 | Citations (PDF) |
| 530 | Variation in morphotype, karyotype and DNA type of fluconazole resistant Candida albicans from an AIDS patient | 2.8 | 12 | Citations (PDF) |
| 531 | The Treatment of Oropharyngeal Candidiasis in HIV-infected Patients with Oral Amphotericin B Suspension | 2.6 | 9 | Citations (PDF) |
| 532 | Polar lipids of Aspergillus fumigatus, A, niger, A, nidulans, A, flavus and A. terreus | 0.6 | 7 | Citations (PDF) |
| 533 | In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B | 3.1 | 58 | Citations (PDF) |
| 534 | Invasive Aspergillosis | 5.2 | 1,570 | Citations (PDF) |
| 535 | In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. | 3.1 | 71 | Citations (PDF) |
| 536 | Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal | 2.5 | 10 | Citations (PDF) |
| 537 | In Vitro Activity of the Echinocandin Antifungal Agent LY303,366 in Comparison with Itraconazole and Amphotericin B against
Aspergillus
spp | 4.1 | 81 | Citations (PDF) |
| 538 | Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant
Aspergillus fumigatus
in a Murine Model of Invasive Aspergillosis | 4.1 | 101 | Citations (PDF) |
| 539 | Diagnostic and Therapeutic Strategies for Invasive Aspergillosis | 2.2 | 21 | Citations (PDF) |
| 540 | Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection | 3.1 | 214 | Citations (PDF) |
| 541 | Echinocandins and pneumocandins--a new antifungal class with a novel mode of action | 3.1 | 121 | Citations (PDF) |
| 542 | Candida inconspicua, a Fluconazole‐Resistant Pathogen in Patients Infected with Human Immunodeficiency Virus | 5.2 | 29 | Citations (PDF) |
| 543 | Amphotericin B resistance testing of Candida spp.: a comparison of methods | 3.1 | 42 | Citations (PDF) |
| 544 | Corticosteroids in pneumococcal meningitis | 3.1 | 0 | Citations (PDF) |
| 545 | A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis | 2.5 | 10 | Citations (PDF) |
| 546 | Prevalence of phthioic acid in Aspergillus species | 0.6 | 8 | Citations (PDF) |
| 547 | Inhibition and interaction of cytochrome P450 ofCandida kruseiwith azole antifungal drugs | 0.6 | 27 | Citations (PDF) |
| 548 | Neurospora sitophila
Pulmonary Infection in a Patient with AIDS | 2.6 | 6 | Citations (PDF) |
| 549 | In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei | 3.1 | 7 | Citations (PDF) |
| 550 | The challenge of invasive aspergillosis: Increasing numbers in diverse patient groups | 2.1 | 17 | Citations (PDF) |
| 551 | Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation | 2.6 | 161 | Citations (PDF) |
| 552 | Azole resistance inCandida | 2.6 | 68 | Citations (PDF) |
| 553 | Atypical eumycetoma caused by Phialophora parasitica
successfully treated with itraconazole and flucytosine | 1.7 | 7 | Citations (PDF) |
| 554 | High incidence of antifungal drug resistance in Candida tropicalis | 3.9 | 18 | Citations (PDF) |
| 555 | Aspergillosis: diagnosis and treatment | 3.9 | 27 | Citations (PDF) |
| 556 | Polarized Growth of Fungal Hyphae Is Defined by an Alkaline pH Gradient | 2.1 | 46 | Citations (PDF) |
| 557 | Rapid genotyping ofEscherichia coli O157 isolates by random amplification of polymorphic DNA | 2.6 | 24 | Citations (PDF) |
| 558 | Acute meningo‐encephalitis in pregnancy—a problem of differential diagnosis | 3.5 | 0 | Citations (PDF) |
| 559 | Characterization of Aspergillus isolates by pyrolysis mass spectrometry | 3.2 | 1 | Citations (PDF) |
| 560 | Aspergillus wound infection following laparostomy | 2.8 | 21 | Citations (PDF) |
| 561 | Isolation of Candida norvegensis from Clinical Specimens: Four Case Reports | 5.2 | 17 | Citations (PDF) |
| 562 | Karyotyping of Fluconazole-Resistant Yeasts with Phenotype Reported as Candida krusei or Candida inconspicua | 1.8 | 24 | Citations (PDF) |
| 563 | Therapeutic Outcome in Invasive Aspergillosis | 5.2 | 669 | Citations (PDF) |
| 564 | Treatment of fungal infection in AIDS | 3.1 | 56 | Citations (PDF) |
| 565 | The Infectious Diseases Manual | 0.1 | 1 | Citations (PDF) |
| 566 | Reviewer's reply | 0.1 | 0 | Citations (PDF) |
| 567 | , a multi-resistant fungus, from a U.K. AIDS patient | 2.8 | 38 | Citations (PDF) |
| 568 | Resistance to fluconazole inCandida albicansfrom AIDS patients correlated with reduced intracellular accumulation of drug | 1.9 | 75 | Citations (PDF) |
| 569 | Anti-Cryptococcus neoformans antibodies during cryptococcosis in patients with the acquired immunodeficiency syndrome | 0.2 | 9 | Citations (PDF) |
| 570 | Antifungal drug susceptibility testing: Working Party of the British Society for Antimicrobial Chemotherapy | 3.1 | 18 | Citations (PDF) |
| 571 | Cure of chronic invasive sinus aspergillosis with oral saperconazole | 0.6 | 12 | Citations (PDF) |
| 572 | Efficacy of oral saperconazole in systemic murine aspergillosis | 0.6 | 37 | Citations (PDF) |
| 573 | Liposomal Amphotericin B (AmBisome) Therapy in Invasive Fungal Infections | 8.1 | 111 | Citations (PDF) |
| 574 | Aspergillus Fungemia: Report of Two Cases and Review | 5.2 | 173 | Citations (PDF) |
| 575 | When to use fluconazole | 62.1 | 0 | Citations (PDF) |
| 576 | Can we prevent azole resistance in fungi? | 62.1 | 50 | Citations (PDF) |
| 577 | Fortnightly Review: Management of genital candidiasis | 0.1 | 29 | Citations (PDF) |
| 578 | Fortnightly Review: Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology) | 0.1 | 67 | Citations (PDF) |
| 579 | Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis | 2.9 | 203 | Citations (PDF) |
| 580 | Evolving Etiology of fungal Infection in the 1990s | 0.2 | 0 | Citations (PDF) |
| 581 | High prevalence of antifungal resistance in Candida spp. from patients with AIDS | 3.1 | 147 | Citations (PDF) |
| 582 | Invasive Aspergillosis in Patients with AIDS | 5.2 | 142 | Citations (PDF) |
| 583 | Administering amphotericin B—a practical approach | 3.1 | 126 | Citations (PDF) |
| 584 | Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards | 4.1 | 59 | Citations (PDF) |
| 585 | Aspergillus Tracheobronchitis | 5.2 | 8 | Citations (PDF) |
| 586 | Diagnosis of infections with Shiga-like toxin-producing Escherichia coli by use of enzyme-linked immunosorbent assays for Shiga-like toxins on cultured stool samples | 1.7 | 11 | Citations (PDF) |
| 587 | Oxygen requirements of Aspergillus species | 1.7 | 69 | Citations (PDF) |
| 588 | Successful Treatment of Sinusitis Caused by Cunninghamella bertholletiae | 5.2 | 42 | Citations (PDF) |
| 589 | Management of deepCandida infection in surgical and intensive care unit patients | 5.2 | 121 | Citations (PDF) |
| 590 | Reply to Troke and Hitchcock's letter | 2.8 | 1 | Citations (PDF) |
| 591 | Treatment of invasive aspergillosis | 2.8 | 63 | Citations (PDF) |
| 592 | Early management of community-acquired asthma | 2.6 | 0 | Citations (PDF) |
| 593 | NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis | 2.0 | 482 | Citations (PDF) |
| 594 | Mycoses in AIDS patients | 0.6 | 55 | Citations (PDF) |
| 595 | Invasive aspergillosis in immunocompromised patients | 3.3 | 49 | Citations (PDF) |
| 596 | Evolving Etiology of Fungal Infection in the 1990s | 0.2 | 4 | Citations (PDF) |
| 597 | Fluconazole-resistant candidosis in an HIV cohort | 2.5 | 137 | Citations (PDF) |
| 598 | Empiric amphotericin B therapy: the need for a reappraisal | 5.1 | 23 | Citations (PDF) |
| 599 | Fluconazole resistance in Candida in patients with AIDS—A therapeutic approach | 2.8 | 89 | Citations (PDF) |
| 600 | Epidemiology of invasive aspergillosis in European cancer centres | 2.6 | 26 | Citations (PDF) |
| 601 | Temperature-dependent expression of elastase inAspergillusspecies | 0.6 | 8 | Citations (PDF) |
| 602 | Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient. | 5.6 | 26 | Citations (PDF) |
| 603 | In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergilus spp. | 3.1 | 28 | Citations (PDF) |
| 604 | Aspergilli — significance as pathogens | 0.6 | 21 | Citations (PDF) |
| 605 | Pregnancy and HIV | 34.5 | 2 | Citations (PDF) |
| 606 | Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations | 5.2 | 212 | Citations (PDF) |
| 607 | Quantitative preservation of viability ofAspergillus fumigatus | 0.6 | 15 | Citations (PDF) |
| 608 | In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents | 1.6 | 144 | Citations (PDF) |
| 609 | Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient | 2.8 | 17 | Citations (PDF) |
| 610 | Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis | 2.8 | 6 | Citations (PDF) |
| 611 | Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis | 2.7 | 45 | Citations (PDF) |
| 612 | Fungal infection in the compromised patient | 2.3 | 0 | Citations (PDF) |
| 613 | The treatment of invasive aspergillosis | 0.2 | 2 | Citations (PDF) |
| 614 | Endophthalmitis in a Patient with Disseminated Cryptococcosis and AIDS Who Was Treated with Itraconazole | 5.2 | 32 | Citations (PDF) |
| 615 | Pulmonary Aspergillosis in the Acquired Immunodeficiency Syndrome | 34.5 | 527 | Citations (PDF) |
| 616 | Neisseria lactamica Meningitis Following Skull Trauma | 5.2 | 31 | Citations (PDF) |
| 617 | Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis | 4.1 | 82 | Citations (PDF) |
| 618 | Ulcerative Tracheobronchitis after Lung Transplantation: A New Form of Invasive Aspergillosis | 3.2 | 265 | Citations (PDF) |
| 619 | Endocarditis Due to Trichosporon beigelii: In Vitro Susceptibility of Isolates and Review | 5.2 | 39 | Citations (PDF) |
| 620 | DNA fingerprinting ofAspergillus fumigatusisolates from patients with aspergilloma | 0.6 | 31 | Citations (PDF) |
| 621 | Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host | 3.1 | 124 | Citations (PDF) |
| 622 | Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment | 4.0 | 70 | Citations (PDF) |
| 623 | In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole againstAspergillus species | 2.6 | 17 | Citations (PDF) |
| 624 | Itraconazole Therapy for Chronic Coccidioidal Meningitis | 9.6 | 144 | Citations (PDF) |
| 625 | Treatment of Coccidioidal Meningitis with Fluconazole | 5.2 | 86 | Citations (PDF) |
| 626 | Transplacental transfer of aflatoxin in humans | 2.8 | 91 | Citations (PDF) |
| 627 | High Serum Concentrations of Aflatoxin in Nepal as Measured by Enzyme-Linked Immunosorbent Serum Assay | 2.9 | 4 | Citations (PDF) |
| 628 | Adverse events associated with itraconazole in 189 patients on chronic therapy | 3.1 | 203 | Citations (PDF) |
| 629 | Restriction Endonuclease Analysis of Total Cellular DNA of Aspergillus fumigatus Isolates of Geographically and Epidemiologically Diverse Origin | 3.7 | 137 | Citations (PDF) |
| 630 | Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations | 1.8 | 85 | Citations (PDF) |
| 631 | Itraconazole in opportunistic mycoses: Cryptococcosis and aspergillosis | 1.8 | 62 | Citations (PDF) |
| 632 | Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases | 5.2 | 847 | Citations (PDF) |
| 633 | Comparison of Guizotia abyssinica seed extract (birdseed) agar with conventional media for selective identification of Cryptococcus neoformans in patients with acquired immunodeficiency syndrome | 4.0 | 29 | Citations (PDF) |
| 634 | Immunoassay of Aflatoxin in Food and Human Tissue | 0.0 | 6 | Citations (PDF) |
| 635 | Itraconazole Therapy for Cryptococcal Meningitis and Cryptococcosis | 8.1 | 181 | Citations (PDF) |
| 636 | Cutaneous Mycobacterium thermoresistibile Infection in a Heart Transplant Recipient | 5.2 | 30 | Citations (PDF) |
| 637 | Clinical Features of Peritoneal Tuberculosis | 3.7 | 4 | Citations (PDF) |
| 638 | Treatment of invasive aspergillosis with itraconazole | 2.0 | 401 | Citations (PDF) |
| 639 | TRANSMISSION OF EPSTEIN-BARR VIRUS BY A TRANSPLANTED KIDNEY, WITH ACTIVATION BY OKT3 ANTIBODY | 2.1 | 20 | Citations (PDF) |
| 640 | New drugs for systemic fungal infections. | 0.1 | 15 | Citations (PDF) |
| 641 | Restriction endonuclease analysis of human and bovine group B streptococci for epidemiologic study | 4.0 | 51 | Citations (PDF) |
| 642 | Measurement of aflatoxin in Nigerian sera by enzyme-linked immunosorbent assay | 1.3 | 18 | Citations (PDF) |
| 643 | An ELISA method for the rapid and simple determination of aflatoxin in human serum | 2.3 | 16 | Citations (PDF) |
| 644 | Analysis of UK Sera for Aflatoxin by Enzyme-linked Immunosorbent Assay | 0.6 | 22 | Citations (PDF) |
| 645 | Infant with two relapses of Group B streptococcal sepsis documented by DNA restriction enzyme analysis | 1.1 | 21 | Citations (PDF) |
| 646 | Skin rash after triple vaccine. | 2.3 | 5 | Citations (PDF) |
| 647 | Neuralgic amyotrophy due to parvovirus infection. | 6.3 | 31 | Citations (PDF) |
| 648 | Renal Aspergilloma—A Case Illustrating the Problems of Medical Therapy | 0.8 | 6 | Citations (PDF) |
| 649 | Acute myelopathy associated with primary infection with human immunodeficiency virus. | 0.1 | 139 | Citations (PDF) |
| 650 | Bacterial infections | 2.0 | 0 | Citations (PDF) |
| 651 | Bacterial infections | 2.0 | 0 | Citations (PDF) |
| 652 | SHOULD TRAVELLERS TO ASIA BE VACCINATED AGAINST JAPANESE ENCEPHALITIS? | 62.1 | 9 | Citations (PDF) |
| 653 | Invasive pulmonary aspergillosis diagnosed by blood culture and successfully treated | 0.5 | 10 | Citations (PDF) |
| 654 | Death Due to Carbamazepine Self-poisoning: Remedies Reviewed | 0.6 | 32 | Citations (PDF) |
| 655 | Failure of single dose amoxycillin as prophylaxis against endocarditis. | 0.1 | 30 | Citations (PDF) |
| 656 | EndogenousCandidaendophthalmitis and osteomyelitis associated with CARD9 deficiency | 0.4 | 33 | Citations (PDF) |
| 657 | Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century | 0.6 | 33 | Citations (PDF) |
| 658 | Aspergillus niger infection in an immunosuppressed patient confined solely to the brain | 0.4 | 11 | Citations (PDF) |
| 659 | Estimated Burden of Serious Fungal Infections in Jamaica | 0.0 | 10 | Citations (PDF) |
| 660 | Chronic Pulmonary Aspergillosis Is a Differential Diagnosis and Co-infection With Nontuberculous Mycobacterial Pulmonary Disease | 5.2 | 2 | Citations (PDF) |
| 661 | Pulmonary Tuberculosis–Associated Chronic Pulmonary Aspergillosis: Urgent Need to Standardize Reporting of Prevalence Studies | 5.2 | 1 | Citations (PDF) |
| 662 | Mortality hazards after treatment completion of pulmonary tuberculosis in a tertiary hospital in Uganda | 1.5 | 1 | Citations (PDF) |
| 663 | Estimated burden of serious mycoses in Poland | 3.4 | 0 | Citations (PDF) |
| 664 | Chronic Pulmonary Aspergillosis Secondary Infection: A Case Report of
Achromobacter
spp. Lung Infection | 0.6 | 0 | Citations (PDF) |
| 665 | Clinical Features and Mortality of Chronic Pulmonary Aspergillosis in Brazil: a Multicenter Cohort Study | 0.8 | 0 | Citations (PDF) |
| 666 | Health disparities and the burden of fungal infections in Africa 0, 4, 100014 | | 2 | Citations (PDF) |
| 667 | P-1728. Causal Machine Learning Algorithm improves the Sensitivity of LDBio Aspergillus ICT IgG/IgM Lateral Flow Assay in the Diagnosis of CPA in Nigeria | 0.8 | 1 | Citations (PDF) |
| 668 | Chronic Pulmonary Aspergillosis in Children: A Scoping Global Review | 0.8 | 0 | Citations (PDF) |
| 669 | Concordance between different methods of detecting fungal-specific IgE antibody in asthma | 2.6 | 0 | Citations (PDF) |
| 670 | SAFS Represents a Particularly Severe Asthma Phenotype | 3.3 | 0 | Citations (PDF) |
| 671 | The black aspergilli (
Aspergillus niger
complex) and their role in human, animal, and plant diseases | 16.7 | 0 | Citations (PDF) |
